| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
867,229 |
| 52
Week Range: |
$187.64 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
19,405 |
57,754 |
513,978 |
| Total Sell Value |
$0 |
$4,136,219 |
$11,851,618 |
$91,955,621 |
| Total People Sold |
0 |
2 |
7 |
9 |
| Total Sell Transactions |
0 |
2 |
21 |
74 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Liu Jean I |
Chief Legal Officer |
• – – |
2022-08-16 |
4 |
AS |
$170.22 |
$278,983 |
D/D |
(1,639) |
88,038 |
|
-27% |
|
| Dansey Roger D |
Interim CEO & CMO |
• – – |
2022-08-16 |
4 |
AS |
$170.22 |
$724,095 |
D/D |
(4,254) |
102,558 |
|
-27% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,014 |
72,294 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,731 |
62,502 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,447 |
143,338 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,731 |
89,677 |
|
- |
|
| Dansey Roger D |
Interim CEO & CMO |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
44,625 |
106,812 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2022-07-05 |
4 |
AS |
$179.46 |
$127,776 |
D/D |
(712) |
48,771 |
|
-25% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2022-06-28 |
4 |
AS |
$180.00 |
$6,234,300 |
D/D |
(34,635) |
62,084 |
|
-27% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2022-06-28 |
4 |
OE |
$65.11 |
$1,285,532 |
D/D |
19,744 |
77,710 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-06-17 |
4 |
AS |
$160.00 |
$181,440 |
I/I |
(1,134) |
119,471 |
|
-21% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-06-17 |
4 |
OE |
$41.04 |
$46,539 |
D/D |
1,134 |
60,198 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-05-24 |
4 |
AS |
$136.40 |
$1,486,377 |
D/D |
(10,866) |
59,064 |
|
4% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-05-24 |
4 |
OE |
$26.10 |
$283,603 |
D/D |
10,866 |
60,337 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2022-05-16 |
4 |
AS |
$134.21 |
$44,691 |
D/D |
(333) |
49,483 |
|
-5% |
|
| Orwin John A |
Director |
– • – |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,503 |
29,003 |
|
- |
|
| Baker Bros. Advisors (gp) Llc |
Director |
– • • |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,006 |
42,966,507 |
|
- |
|
| Gryska David W |
Director |
– • – |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,503 |
47,753 |
|
- |
|
| Love Ted W |
Director |
– • – |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,503 |
4,704 |
|
- |
|
| Simonian Nancy A |
Director |
– • – |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,503 |
54,003 |
|
- |
|
| Seth Alpna |
Director |
– • – |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,503 |
12,953 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,503 |
9,649 |
|
- |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-05-12 |
4 |
AS |
$125.39 |
$2,142,117 |
D/D |
(17,043) |
666,060 |
|
11% |
|
| Siegall Clay B |
President & CEO |
• • – |
2022-05-12 |
4 |
OE |
$26.10 |
$444,822 |
D/D |
17,043 |
676,653 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2022-04-21 |
4 |
AS |
$144.15 |
$93,986 |
D/D |
(652) |
76,975 |
|
9% |
|
1805 Records found
|
|
Page 7 of 73 |
|
|
